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Table 1. Early febrile and documented infectious episodes among 54 HCT patients.
Febrile episodes DIE CDI MDI Bacteremia IFI
N episodes in all patients 24 14 1 4 10 0
Incidence per 100 patients (n5 54) 44 26 2 7 19 0
Incidence per 1000 neutropenia
days (n5737)
32 19 1 5 14 0
Specific presentation or pathogen N/A N/A Pneumonia Influenza A (n51),
CMV (n51), Clostridium
difficile (n51), Coagulase
negative staphylococci
Escherichia coli (n55), Stenotrophomonas
maltophilia (n51), Coagulase negative
staphylococci (n51), Staphylococcus
aurus (n51), Streptococcus pneumonia
(n51), Enterococcus (n51)
N/A
DIE – documented infectious episodes, CDI – clinical documented infections, MDI – microbiology documented infections, IFI – invasive fungal infections,
N/A – not applicable.
Poster Session II S347HCT. We hypothesized that early febrile or documented infectious
episodes (from day 0 through engraftment) would promote the de-
velopment of aGVHD. Data regarding febrile episodes (defined as
clinically and/or microbiologically documented infections or epi-
sodes with fever . 380C for two consecutive days to exclude drug
and blood-product-related fever) were prospectively collected for
patients undergoing HCT. In addition, all patients’ charts were ret-
rospectively reviewed for the onset, staging/grading of aGVHD and
for patient-donor characteristics. 54 consecutive patients undergo-
ing HCT were included. Median patient age was 51 (range, 22-67)
years. Preparative regimen was myeloablative (MA) (n 5 23) or re-
duced intensity (n 5 31) conditioning. 27 pts received peripheral
blood stem cells (PBSC) fromHLA-identical siblings, 25 patients re-
ceived PBSC from unrelated donors (19 HLA-matched PBSC and 6
received 1-HLA-Agmismatched PBSC) and 2 patients received dou-
ble umbilical cord blood graft. Post-grafting immunosuppression
consisted of combined cyclosporine with either methotrexate or my-
cophenolate mofetil. Patients receiving an unrelated donor graft
were also given ATG. By day 120, 34 pts (63%) developed grade
2-4 aGVHD. 24 pts developed febrile episode, 14 of whom had
documented infectious episodes (clinical documented infection,
n 5 1; microbiology documented infection, n 5 3 and bacteremia,
n 5 10).Patients who developed a febrile episode had a higher risk
for developing grade 2-4 (OR 5 5.7, 95% CI 1.6-20.8, p\ 0.05)
and grade 3-4 (OR 5 3, 95% CI 0.8-10.6, p 5 0.08) aGVHD.
Among other risk factors for aGVHD (MA conditioning, female do-
nor to male recipient, unrelated donor and 1-HLA-Ag mismatched
graft), only MA conditioning was associated with an increased risk
for aGVHD with borderline statistical significance (OR 5 2.8,
95%CI 0.8-9.5, p5 0.09).We conclude that febrile episodes occur-
ring early, before engraftment, are associated with higher risk for
GVHD. Confirmation of these findings in larger cohorts is war-
ranted. The types of infections possibly promoting aGVHD should
be defined.540
ETANERCEPT FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Park, J.S., Jeong, S.H., Ahn, M.S. Ajou University School of Medicine,
Suwon, Kyunggi-do, Korea
Treatment strategy for steroid-refractory acute graft-versus-host
disease (GvHD) after allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) needs to be standardized.We report our clinical
experience of the effect of etanercept on steroid-refractory acute
GvHD. A total of 18 consecutive patients with steroid-refractory
acute GvHD were retrospectively studied. Twenty-five milligrams
of etanercept were given subcutaneously twice weekly for four weeks.
Clinical responses were evaluated with regard to the severity of acute
GvHD. The median age of patients was 43.5 years. Before etaner-
cept, grade IV, grade III, grade II, and grade I acute GvHDoccurred
in seven, six, five, and zero patients, respectively; however the num-
ber of patients changed to four, five, five, and four, respectively, afteretanercept (p.005). Eighty percent of grade II, 14% of grade III, and
57% of grade IV patients showed a partial response. Skin and gut
GvHD were well controlled with etanercept, whereas hepatic
GvHD was not. Three patients died of fatal infection. There were
no factors affecting the clinical outcome of etanercept. All the
non-responders died and 56.6% of the responders survived
(p0.0008). Etanercept can be effective in treating steroid-refractory
acute GvHD after allo-HSCT, with tolerable side effects.541
THE ROLE OF PLASMA CYTOKINES IN THE DIAGNOSIS OF AUTOIMMUNE
PHENOMENA IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
UNDERGOING NOVEL ANTI-MYELOMA THERAPIES AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (AUTO-HCT)
Veeraputhiran, M., Sanath Kumar, N., Haider, S., Barlogie, B., Van
Rhee, F., Anaissie, E. University of Arkansas for Medical Sciences, Little
Rock, AR
Introduction: Auto-immune (AI) phenomena among MM patients
receiving novel agents and auto-HCT usually present with fever,
skin rash and include a transient engraftment syndrome (ES) or
more serious complications, Graft vs. Host Disease (GvHD) and
DRESS (drug rash with eosinophilia and systemic syndrome) with
the latter two requiring specific therapies.The clinical characteristics
of these 3 syndromes may overlap, complicating patient manage-
ment. We evaluated a set of clinical and laboratory diagnostic crite-
ria, including a plasma cytokine (PC) panel, to help diagnose these
clinical syndromes.
Patients andMethods: A retrospective review of medical records of
MMpatients (pts) who developed a skin rash between 2007 and 2010
and on whom PC panels were obtained. Clinical findings including
fever, skin rash, results of skin biopsies (SBx), clinical recurrence of
symptoms during tapering of therapy were evaluated. Laboratory
values evaluated included eosinophilia, liver and renal function tests,
plasma cytokines levels {soluble interleukin -2 (IL-2) receptor,
IL-4,5,6,8,10, IFN g, TNF-a, Eotaxin-3 and Eosinophil derived
neurotoxin (EDN)}. The mean, median and range of lab results
were calculated.
Results: pts were categorized into 4 groups: DRESS (n 5 25),
GVHD (n 5 6), ES (n 5 4), simultaneous DRESS and GVHD
(n5 1) and controls (29 pts without AI phenomena). The incidence
of eosinophilia and liver dysfunctionwere significantly higher among
pts with DRESS vs. those with GvHD, ES and controls. SBx results
differed between pts with DRESS (spongiosis and/or increased eo-
sinophils, 95% of pts) and those with GvHD (67% had any 2 of
the following: interface dermatitis, baso-vacuolation or peri-vascular
lymphocyte infiltration). The mean of PC, characteristics of eosino-
phil involvement were significantly elevated among pts with DRESS
compared with GVHD, ES or controls including higher values for
IL-5 (31.9 pg/mL in DRESS vs. 4 pg/mL in control), eotaxin-3
(24.5 pg/mL vs. 13.3 pg/mL) and EDN (98.8ng/mL vs. 17.5ng/
mL). Recurrence of events was noted among 7 of 25 pts with DRESS
vs. 1 of 6 and none of 4 among those with GVHD and ES, respec-
tively.
S348 Poster Session IIConclusion: Levels of PC, especially IL-5, EDN and eotaxin may
help in the differential diagnosis of AI phenomena (DRESS,
GvHD and ES) following therapy with novel anti-myeloma agents
and auto-HCT.These diagnostic tests may enable directed therapies
for pts withDRESS andGvHD.More effective therapies forDRESS
are needed.542
ATTEMPTED STEM CELL TRANSPLANT FOR APLASTIC ANEMIA SECOND-
ARY TO GVHD FROM A CADAVERIC RENAL TRANSPLANT
Burns, K.M., Dilioglou, S., Eagar, T., Divatia, M., Land, G. The Meth-
odist Hospital, Houston, TX
Introduction: Graft versus Host Disease (GVHD) is a common
complication encountered with hematopoetic stem cell (HSC) trans-
plantation, however it is a rare complication of solid organ transplan-
tation or transfusion. We report a case of GVHD from a renal
allograft that was not detected until the patient developed aplastic
anemia.
Case Report: A 56-year-old male with end stage renal disease re-
ceived a 5 of 6 antigen-mismatch cadaveric donor renal allograft.
On post-operative day (POD) 58 a scaly puritic skin rash developed
and was treated with topical steroids. Bone marrow biopsies re-
vealed trilineage aplasia with\ 1% cellularity and STR analysis
confirmed chimerism with 83% of the blood mononuclear cells
(MNCs) originating from the kidney donor. In addition, the pa-
tient was treated for CMV viremia, enterococcus faecalis and stenotro-
phomonas maltophilia bacteremia, and HSV stomatitis. On POD
118 the patient received HSC transplantation with his HLA-
matched sibling. The patient experienced acute renal insufficiency
requiring intermittent dialysis, ilius with abdominal distension
requiring nasogastric suctioning and bowel rest, and on POD
135 developed respiratory distress necessitating intubation and
ventillator support and the patient expired after two episodes of
cardiac arrest due to overwhelming sepsis.
Discussion: The severity of GVHD varies depending on multiple
factors, and is particularly related to the type of allograft trans-
planted. Transfusion associated GVHD (TA-GVHD) is well recog-
nized to have a remarkably higher overall mortality thanGVHDdue
to HSC transplantation. GVHD secondary to solid organ transplan-
tation is most often associated with liver and intestinal transplants
with an incidence of about 1% and mortality reports ranging from
50-75%. GVHD due to passenger lymphocytes in solid organ trans-
plants have much higher mortality rates than GVHD from HSC
transplantation and almost approaches the mortality rate of TA-
GVHD (. 90%). The high mortality rates of TA-GVHD and solid
organ transplant associated GVHD are due to the complications of
aplastic anemia, i.e., infection and bleeding. Patients should be mon-
itored for potential GVHD after renal transplantation to allow ear-
lier recognition and potential interventions to attempt to improve
the mortality rates from this complication.543
HIGH INCIDENCE OF HYPERACUTE GVHD (HAGVHD) IN PATIENTS (PTS)
UNDERGOING UNRELATED DONOR ALLOGENEIC HEMATOPOEITIC STEM
CELL TRANSPLANTATION (URALLOHSCT) RECEIVING A NON-METHO-
TREXATE (NON-MTX) CONTAINING REGIMEN
Nathan, S., Jimenez, A.M., Maciejewski, J., Rich, E.S., Lo, M.,
Schultz, K., Fung, H. Rush University Medical Center, Chicago, IL
Background: HaGVHD is a syndrome characterized by unex-
plained fevers, diarrhea, skin rash and hepatic toxicity that occurs be-
fore engraftment (less than 14 days) in alloHSCT pts and is
associated with significant morbidity and mortality. We describe
the incidence and clinical characteristics of URalloHSCT recipients
in our institution that developed this complication after we adopted
a new policy in GVHD prophylaxis that aborted the use of MTX.Patients andMethods:Data from 14 consecutiveURalloHSCTpts
over a 1 year period were reviewed. 9 pts with a diagnosis of
haGVHD were identified based on the clinical criteria of nonbac-
teremic fever with rapid development of skin rash involving .
25% BSA or early onset diarrhea or worsening hepatic function
without an identifiable cause prior to engraftment. Demographics,
indication for transplantation, type and sex of donor, conditioning
regimen (CR),GVHDprophylaxis, engraftment day and clinical fea-
tures of haGVHD were identified and collected.
Results: 14 pts underwent an URalloHSCT at our institution from
2009-10. 9 (64.28%) pts (average age 42.89 yrs, range 21-63 yrs)
were diagnosed with haGVHD per clinical criteria. 6 (66.7%) pts
were male and 3(33.3%) pts female. Indications for transplant in-
cluded relapsed/ refractory non Hodgkin lymphoma, Hodgkin lym-
phoma, acute myelogenous leukemia, acute lymphocytic leukemia
and therapy related myelodysplastic syndrome. 8 (88.9%) pts re-
ceived a myeloablative CR. 4 (44.4%) pts had a HLA mismatched
and 6 (66.6%) pts had a sex mismatched donor. All pts had received
GVHD prophylaxis with a calcineurin inhibitor combination (7/9
Tacrolimus/Sirolimus and 2/9 cyclosporine/mycophenolatemofetil)
without methotrexate with 5 pts receiving ATG in addition. Fever
developed at median +5.11 days (range 1-11days), diarrhea devel-
oped on median +2.7 days (range 1-4 days) after stem cell infusion.
Conclusions: We conclude that utilizing a non-methtrexate
containing GVHD prophylaxis regimen in the unrelated allogeneic
hematopoietic stem cell transplantation setting is associated with
a high incidence of hyperacute GVHD. This maybe attributable to
the absence of methotrexate with increased risk conferred by the
myeloablative conditioning regimen and mismatched HLA and sex
of donors. The addition of ATG did not confer any benefit. There-
fore a non-methotrexate containing GVHD prophylaxis regimen in
this patient population should be used cautiously outside of a clinical
trial.544
DERMATOLOGY CONSULTATION FOR CUTANEOUS COMPLICATIONS OF
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Gordon, J.1, Rademaker, A.2, Mehta, J.3, Cotliar, J.1 1Northwestern
University, Chicago, IL; 2Northwestern University, Chicago, IL; 3North-
western University, Chicago, IL
Background: The acute onset of a skin eruption early in the post-
transplant course of the hematopoietic stem cell transplant
(HSCT) patient is challenging due to the clinical similarity of erup-
tions that are common in this population. These include of morbilli-
form drug eruptions, viral exanthema, eruption of lymphocyte
recovery, erythema multiforme, toxic erythema of chemotherapy,
and acute graft-versus-host disease (GVHD). We aimed to identify
cutaneous eruptions in HSCT patients in the early post-transplant
period, and the incidence of dermatologic consultation, along with
the utility of skin biopsies and whether a change in management
resulted from the consultation.
Methods: A retrospective chart review was performed on patients at
Northwestern Memorial Hospital who underwent their first allo-
genic or autologous HSCT in 2009. Information collected included
incidence and presentation of cutaneous complications (including
GVHD), as well as frequency and outcome of dermatologic consul-
tation (including changes in patient management as a result of con-
sultation).
Results:We found 220 patients who received a HSCT in 2009. To
date, 126 (80 autologous, 46 allogeneic) of these have been analyzed.
Preliminary data shows that 50/126 (39.7%) patients had cutaneous
complications in the early post-transplant period, and of these, 21/50
(42.0%) were diagnosed with acute GVHD. Dermatology was con-
sulted for 29/50 (58.0%) patients with rash and a skin biopsy was per-
fomed on 16/29 (55%) patients seen by dermatology. Treatment
plans were changed after dermatologic consultation in 15/29
(51.7%) patients.
Conclusion:Dermatologic consultation for the recognition and di-
agnosis of the early cutaneous complications of HSCT is a valuable
resource that often leads to changes in patient management. Further
studies are necessary to analyze whether patient outcomes are af-
fected by dermatologic consultation.
